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Genetic diversity and antifungal susceptibility
profiles in causative agents of sporotrichosis
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Abstract
Background: Sporotrichosis is a chronic subcutaneous mycosis of humans and animals, which is typically acquired
by traumatic inoculation of plant material contaminated with Sporothrix propagules, or via animals, mainly felines.
Sporothrix infections notably occur in outbreaks, with large epidemics currently taking place in southeastern Brazil
and northeastern China. Pathogenic species include Sporothrix brasiliensis, Sporothrix schenckii s. str., Sporothrix
globosa, and Sporothrix luriei, which exhibit differing geographical distribution, virulence, and resistance to
antifungals. The phylogenetically remote species Sporothrix mexicana also shows a mild pathogenic potential.
Methods: We assessed a genetically diverse panel of 68 strains. Susceptibility profiles of medically important
Sporothrix species were evaluated by measuring the MICs and MFCs for amphotericin B (AMB), fluconazole (FLC),
itraconazole (ITC), voriconazole (VRC), posaconazole (PCZ), flucytosine (5FC), and caspofungin (CAS). Haplotype
networks were constructed to reveal interspecific divergences within clinical Sporothrix species to evaluate
genetically deviant isolates.
Results: ITC and PCZ were moderately effective against S. brasiliensis (MIC90 = 2 and 2 μg/mL, respectively) and S.
schenckii (MIC90 = 4 and 2 μg/mL, respectively). PCZ also showed low MICs against the rare species S. mexicana. 5FC,
CAS, and FLC showed no antifungal activity against any Sporothrix species. The minimum fungicidal concentration
ranged from 2 to >16 μg/mL for AMB against S. brasiliensis and S. schenckii, while the MFC90 was >16 μg/mL for
ITC, VRC, and PCZ.
Conclusion: Sporothrix species in general showed high degrees of resistance against antifungals. Evaluating a
genetically diverse panel of strains revealed evidence of multidrug resistant phenotypes, underlining the need for
molecular identification of etiologic agents to predict therapeutic outcome.
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Background
Sporotrichosis is a (sub)cutaneous mycosis of man and
animals that is highly prevalent in tropical and subtrop-
ical areas, and currently reaching epidemic proportions
in Brazil [1-3] and China [4,5]. Over the last decade,
sporotrichosis has changed from a relatively obscure en-
demic infection to an epidemic zoonotic health problem
in the South and Southeast Regions of Brazil [2]. Infec-
tion typically occurs by cutaneous inoculation of the
microorganism from environmental sources [6,7] or via
zoonotic transmission [3]. Sporotrichosis is a chronic
disease that can spread lymphatically and most often
presents as a localized lesion with subcutaneous nodules
that eventually break through the skin [7,8]. Although
rare, hematogenous dissemination can also occur de-
pending on the immune status of the host [9].
Recent studies on molecular phylogeny clarified species
boundaries within clinical isolates of Sporothrix and pro-
vided strong support for many cryptic groups. The major
causative agents of sporotrichosis are several closely
related thermodimorphic fungi of the genus Sporothrix
[10,11], including Sporothrix brasiliensis, Sporothrix
schenckii s. str., Sporothrix globosa, and Sporothrix luriei
[2,5]. These species have distinct virulence profiles [12],
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karyotypes [13] and geographic distributions ranging
from regional [1,10] to global [5]. The Sporothrix genus,
embedded in the plant-associated order Ophiostomatales,
exhibits high genetic diversity [10,11], which is accompan-
ied by a diversity of in vitro responses to the main antifun-
gal agents [14] used in sporotrichosis treatment [7,15].
Such agents include potassium iodide [16] and itracona-
zole [17] for localized cutaneous and lymphocutaneous
forms, and amphotericin B for disseminated cases [6,9,16].
Screening for antifungal susceptibilities during epi-
demiological surveillance programs could help to un-
cover putative multidrug resistant Sporothrix strains,
and improve our ability to adjust therapeutic regimens
and reduce relapse.
Despite the considerable spread of the Brazilian
epidemic of sporotrichosis over the last two decades
[1-3,10] and the increased occurrence of atypical cases
[9], no study of this illness to date has integrated mo-
lecular epidemiology and antifungal drug susceptibility.
The present study aimed to evaluate the resistance profiles
to currently used antifungals in a genetically diverse panel




This study included 68 Sporothrix isolates that were
obtained from clinical lesions of patients with varying
degrees of disease severity (n = 65 human/n = 2 animal)
or from environmental sources (n = 1). The isolates were
originally received as S. schenckii s.l., and were subse-
quently identified down to the molecular species level by
Rodrigues et al. [1,3,18] and Fernandes et al. [12,19]
(Additional file 1: Table S1). Isolates were stored at room
temperature in slant cultures on Sabouraud dextrose agar
(SDA; Difco Laboratories, Detroit, MI). Ethical approval
was provided by Institutional Committee (UNIFESP-
0244/11).
Antifungal agents and susceptibility testing
Culture conditions and inoculum preparation were as
described by Marimon et al. [14]. Using the methods
recommended in the CLSI standard document M38-A2,
we evaluated minimum inhibitory concentrations (MIC)
for the following seven antifungal agents: amphotericin B
(AMB), fluconazole (FLC), itraconazole (ITC), vorico-
nazole (VRC), posaconazole (PCZ), flucytosine (5FC),
and caspofungin (CAS). The final drug concentrations
ranged from 0.03 to 16 μg/mL for AMB, ITC, VRC,
PCZ, and CAS, and from 0.12 to 64 μg/mL for 5FC
and FLC. The microplates were incubated at 35°C and
read after 72 h. Candida parapsilosis ATCC 22019 and
Candida krusei ATCC 6258 were used as quality controls
for the experiments.
To obtain the minimum fungicidal concentration (MFC),
for each serial dilution, 10 μL was taken from each well
with no visible growth and spread on Sabouraud dextrose
agar (Difco Laboratories, USA). Plates were then incubated
at 28°C for 48–72 h. The MFC was defined as the lowest
drug concentration that yielded three or fewer colonies, i.e.,
95.5 to 99% killing activity [20]. The Mann–Whitney U test
was used to determine the distribution of MIC and MFC
data. A p value of <0.05 was considered to indicate statis-
tical significance.
Molecular characterization
The isolates were genetically characterized [1,10] based
on calmodulin gene sequencing using the primers CL1
(5′-GAR TWC AAG GAG GCC TTC TC) and CL2A
(5′-TTT TTG CAT CAT GAG TTG GAC) [21], as well
as sequencing part of the rRNA operon [5] using the
primers ITS1 (5′-TCC GTA GGT GAA CCT TGC GG)
and ITS4 (5′-TCC TCC GCT TAT TGA TAT GC) [22].
We choose these loci because they have previously been
extensively used for phylogeny and taxonomy of this
complex of cryptic species [1-3,5,10,11,23]. To increase
the quality of sequence data, sense and antisense se-
quences were determined with an ABI 3730 DNA Ana-
lyser (Applied Biosystems, Inc., Foster City, CA, USA) and
thereafter assembled into single sequences via CAP3 using
bases with a Phred quality score of ≥30. All sequences
were deposited online at GenBank (Additional file 1:
Table S1).
Phylogenetic histories were reconstructed using max-
imum likelihood (ML) and neighbor-joining (NJ) methods
with the Mega5 software [24], using 1,000 bootstrap
replicates to estimate the confidence values for individual
branches [25]. Evolutionary distances were calculated
using the Tamura 3-parameter model [26]. The rate of
change between sites was modeled with a gamma distribu-
tion (shape parameter = 1). Nucleotide (π) and haplotype
(Hd) diversities [27] were estimated using DnaSP software
version 5.10 [28]. Haplotype networks were used to
visualize differences and diversity among S. brasiliensis
and S. schenckii sequence data [28]. Gaps and missing
data were excluded in the calculations. Median-joining
networks [29] for the concatenate dataset (CAL + ITS)
were obtained and visualized using the Network 4.610
software, as previously described by Rodrigues et al. [3].
Results
The combined dataset (CAL + ITS) yielded a sequence
alignment of 1,397 positions, including 866 invariable
characters, 232 variable parsimony-informative sites
(16.6%), and 185 variable singletons. The topologies of
the ML and NJ trees were congruent (Icong = 3.66; p = 1.68
e-24) [30] and the isolates were distributed among the
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six major clades (Figure 1), in agreement with previous
studies [1-3,10,11].
Table 1 summarizes the MIC and MFC ranges for the
human clinical Sporothrix isolates. Sporothrix brasiliensis
exhibited low genetic diversity (π = 0.00194), and com-
prised seven haplotypes (H1–H7). Of the tested drugs,
the triazoles ITC and PCZ showed the best activity
against S. brasiliensis strains, with MICs ranging from
0.25 to 4 μg/mL (Figure 2A) and from 0.5 to 2 μg/mL
(Figure 2C), respectively. The MICs for ITC were lower
in S. brasiliensis compared to in S. schenckii (p = 0.0001)
and S. mexicana (p = 0.0031). We detected moderate
activity for the polyene AMB against S. brasiliensis strains,
with MICs ranging from 1 to 8 μg/mL (Figure 2E), while
CAS, 5FC, FLC, and VRC showed poor activity.
Sporothrix schenckii represented by the genetically
heterogeneous clade II (π = 0.00917) was divided into
ten haplotypes (H8–H18) and showed a broad MIC
range for the different antifungals. ITC (Figure 2A) and
PCZ (Figure 2C) presented good activity against most
S. schenckii s. str. strains, with MICs ranging from 0.25
to >16 μg/mL and from 0.06 to >16 μg/mL, respectively.
The MICs for PCZ were slightly higher in S. schenckii
compared to in S. brasiliensis (p = 0.0076). AMB presented
Figure 1 Phylogenetic relationships of calmodulin-encoding gene and ITS sequences among clinical and environmental Sporothrix
species. The phylogenetic tree were estimated in MEGA5 using the Tamura 3-parameter model. The numbers close to the branches represent
indices of support (NJ/ML) based on 1,000 bootstrap replications. The branches with bootstrap support higher than 70% are indicated in bold.
Haplotypes numbers were assigned to each isolate and are indicated inside the circles.
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Table 1 Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of clinical isolates belonging to the Sporothrix schenckii
complex
Species AMB (μg/mL) FLC (μg/mL) ITC (μg/mL) VRC (μg/mL) PCZ (μg/mL) 5FC (μg/mL) CAS (μg/mL)
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
S. brasiliensis (n = 22) Range 1-8 2 - >16 >64 >64 0.25 - 4 1 - > 16 2 - >16 16 - >16 0.5 - 2 1 - >16 64 - >64 >64 >16 >16
50% 4 4 >64 >64 1 16 16 >16 1 >16 >64 >64 >16 >16
90% 4 16 >64 >64 2 >16 >16 >16 2 >16 >64 >64 >16 >16
S. schenckii (n = 39) Range 1 - >16 2 - >16 >64 >64 0.25 - >16 0.5 - > 16 4 - >16 4 - >16 0.06 - >16 1 - >16 64 - >64 64 - >64 2 - >16 >16
50% 8 16 >64 >64 1 16 16 >16 1 >16 64 >64 >16 >16
90% >16 >16 >64 >64 4 >16 >16 >16 2 >16 >64 >64 >16 >16
S. globosa (n = 4) Range 2 - >16 4 - >16 >64 >64 0.5 - >16 0.5 - >16 2 - 8 8 - >16 0.5 - 16 1 - >16 8 - >64 >64 8 - > 16 >16
50% - - - - - - - - - - - - - -
90% - - - - - - - - - - - - - -
S. mexicana (n = 3) Range 8 - >16 8 - >16 >64 >64 2 - >16 2 - >16 1 - >16 16 - > 16 1 - >16 >16 64 - >64 >64 8 - >16 >16
50% - - - - - - - - - - - - - -
90% - - - - - - - - - - - - - -
Overall (n = 68) Range 1 - >16 2 - >16 >64 >64 0.25 - >16 0.5 - >16 1 - >16 4 - >16 0.06 - >16 1 - >16 8 - >64 64 - >64 2 - >16 >16
50% 4 16 >64 >64 1 >16 16 >16 1 >16 >64 >64 >16 >16



















Figure 2 (See legend on next page.)
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high MICs against S. schenckii isolates, ranging from 1
to >16 μg/mL (Figure 2E), while the remaining compounds—
CAS, 5FC, FLC, and VRC—showed very poor activities.
Each of the evaluated drugs demonstrated poor in vitro ef-
ficacy against the tested S. globosa (H20) and S. mexicana
(H21) strains (Figure 2).
As expected, MFCs were at least two-fold higher than
the MICs for each drug (Figure 2B, D and F). AMB pre-
sented lower MFC values compared to those obtained for
the other tested drugs (p = 0.0011; Figure 2F). The MFC
for AMB was also lower among S. brasiliensis isolates
compared to in S. schenckii (p = 0.0001) and S. mexicana
(p = 0.0361). Evaluating the MIC and MFC values together,
we identified several multidrug resistant isolates among
the S. schenckii s. str. strains. In particular, the deviating
haplotype 12 (H12; Figure 2B, D and F), which was rep-
resented by a Brazilian strain of human origin (Ss51),
showed cross-resistance to all azole drugs and polyenes.
Discussion
Given the high intrinsic antifungal resistance in Sporothrix,
studies correlating antifungal susceptibility and genetic
diversity among etiological agents of sporotrichosis are
overdue. Here we used haplotype networks to estimate
genetic diversity among clinical Sporothrix species. This
approach has the strength of enabling the recognition of
genetically deviating strains in a population, rather than
randomly sampled frequent haplotypes with similar
genetic background, as represented by the frequent hap-
lotypes H1 and H8 in the S. brasiliensis and S. schenckii
populations, respectively. However, haplotype-based
strategies are dependent on the molecular marker used
to estimate diversity, the set of strains comprising the
database as well as the network methods [31]. To date, the
partial sequence of CAL and ITS region (ITS1/2 + 5.8 s)
has been used to estimate genetic diversity and taxonomy
of clinical Sporothrix species [2,5,10,11]. Indeed, due to
its highly discriminatory power and polymorphisms we
choose these regions to give insights into the genetic
diversity in sympatric populations of S. brasiliensis and
S. schenckii s. str.
A genetically homogeneous population may be ex-
pected to have similar susceptibility profiles among the
individuals, but increased fitness during population ex-
pansion can result in a diversity of susceptibility profiles.
Alternatively, differential responses may emerge over
time in ancestral genetically diverse species. Of the
phylogenetically related species S. brasiliensis and S.
schenckii s. str., the former has a lower genetic diversity
[2,3,10,13], and here we found that it also had a corres-
pondingly lower variability of in vitro susceptibility. A
larger degree of genetic diversity has been observed
among S. schenckii s. str. isolates, which is accompanied
by greater variation in antifungal profiles [14] virulence
[12] and genomic organization [13]. Moreover, the pres-
ence of median vectors (mv1-3, 5, 6) in the haplotype
network (Figure 2) may indicate extinct or intermediate
unsampled haplotypes within the S. schenckii s. str. pop-
ulations, possibly suggesting the existence of even more
variation. Conversely, the absence of median vectors in
the S. brasiliensis population strongly suggests that our
analysis detected most of the strain diversity circulating
in the human epidemic, thus supporting the low vari-
ation of the MIC and MFC values in this species.
Itraconazole is the drug of choice for treating endemic
mycoses caused by thermodimorphic fungi, including
sporotrichosis. Our findings regarding the in vitro activ-
ities of the main antifungal drugs are in agreement with
previous studies, indicating that ITC and PCZ were mod-
erately effective against isolates of S. brasiliensis and S.
schenckii s. str. [14,32]. Despite the relatively high values
found in all studies, several authors have demonstrated
the efficacy of ITC in clinical outcome. Barros et al. [17]
studied the clinical treatment of a large number of patients
in Rio de Janeiro, and reported the success of ITC
treatment (50–400 mg/day) in 94.6% patients (n = 610).
Although this study did not molecularly identify the
phylogenetic species involved, it was most likely S.
brasiliensis, as this species is highly prevalent in Rio de
Janeiro due to feline sporotrichosis outbreaks [1-3,10].
Such an epidemiological profile could explain the favor-
able results for ITC. The relatively low MICs found for
PCZ also suggest this molecule to be a promising drug in
the treatment of sporotrichosis caused by S. schenckii s.
str. or S. brasiliensis. Additionally, PCZ also showed low
MICs against 2 out of 3 clinical isolates of the rare species
S. mexicana, including CBS 132928 (MIC = 1 μg/mL) and
CBS 132927 (MIC = 2 μg/mL). Only a few strains of S.
mexicana have been described in the literature [1,10], and
the species has been reported as tolerant to most commer-
cially available drugs [14,33].
Resistance to amphotericin B has been reported in
emerging pathogens, such as Aspergillus terreus, Candida
lusitaniae, Fusarium spp., Scedosporium prolificans, and
(See figure on previous page.)
Figure 2 Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. Median-joining haplotype network
of Sporothrix schenckii complex isolates based on calmodulin and ITS concatenated sequences. The circumference size is proportional to the
haplotype frequency. Black dots (median vectors) represent unsampled or extinct haplotypes in the population. Mutational steps are represented
by white dots and, in cases of long branches, by values. The charts represent the MIC (A, C, and E) and MFC (B, D, and F) distributions within
the population for ITC, PCZ, and AMB.
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Trichosporon asahii [34,35]. Here we found high MICs for
AMB in five isolates of S. schenckii s. str. (Ss17, Ss22,
Ss110, and Ss119 from H8, and isolate Ss51 from H12)
with MIC and MFC values of >16 μg/mL. The multidrug
resistant phenotype found for isolate Ss51 (H12; Figure 2B,
D, and F) is particularly noteworthy in relation to its clin-
ical origin, where it showed moderate virulence in a mur-
ine model [12]. The high MICs found for the remaining
compounds (FLC, VRC, CAS, and 5FC) are in agreement
with previous reports [14,32,36].
Fungistatic drugs are capable of inhibiting the cell growth
and reproduction of fungi without destroying them. Drug-
sensitive pathogens may evolve resistance under the select-
ive pressure imposed by continuous exposure to fungistatic
drugs [37]. The molecular mechanism that lies behind
the recent emergence of drug-resistant phenotype among
Sporothrix species is currently unknown. However, judging
from other fungi, the increased and prolonged use of tria-
zoles has raised concerns about resistant infections by
Cryptococcus neoformans [38], Candida albicans [39] and
Aspergillus fumigatus [40]. Azole resistance may occur
through a diversity of mechanisms including the upregula-
tion of multidrug transporter genes that leads to enhanced
efflux of azoles and therefore reduce drug accumulation
[41]; multiple genetic alterations of the target enzyme that
can affect the affinity of the enzyme and therefore pre-
vents azole binding [42], and alteration of metabolism,
usually sterol synthesis [43]. More recently, genetic studies
correlating antifungal resistance and alteration in chromo-
some copy number and genomics architecture has deliv-
ered an exciting view on the molecular mechanisms
governing the increased fitness to the phenotype of azole-
resistance [38,44-46].
Candida albicans [39,44,45] and Cryptococcus neofor-
mans [38,46,47] triazole-resistant isolates very often con-
tain an abnormal number of chromosomes. Such genomic
plasticity may offer additional copies of drug resistance
genes leading chromosomal aneuploidies isolates to over-
coming the drug effects [44,45] and allowing rapid adap-
tive evolution [47]. Although this phenomenon may occur
spontaneously [47], drug-resistant aneuploidies arise very
frequently within drug-exposed fungal populations and
this may support our recent findings on chromosomal
polymorphisms in Sporothrix species [13]. The intra-
specific polymorphisms in chromosome number and size
in S. schenckii s. str. suggested that aneuploidy occur
among clinical isolates, and it is tempting to hypothesize
that this phenomenon could, in part, be responsible for
the differences in drug profiles observed here. Therefore,
the high karyotype diversity observed for S. schenckii s. str.
[13] is reflected in the genetic diversity found in our
haplotype network (Figure 2). However, testing for this
pattern requires a larger number of isolates with dissimilar
antifungal profiles as well as chromosomal polymorphism.
Fungicidal drugs may be defined as those that lead to
a reduction of 99.9% of the initial inocula [48]. It is diffi-
cult to make comparisons between published MFCs stud-
ies, since most were performed before the introduction of
clinical species beyond S. schenckii s. str. to the genus
Sporothrix. Two or more of these newer species were
likely involved in the studies of McGinnis et al. [49] and
Silveira et al. [50]. In all clinical Sporothrix spp. evaluated,
we found significant differences between the minimum
concentrations needed to inhibit fungal cell growth and
the concentration required for colony count reduction.
In all studied species, most isolates were able to grow
after 72 h in the presence of each drug at the maximum
concentration tested, which is in agreement with results
obtained by Trilles et al. [36]. The moderately low MICs
for triazoles imply a great resistance to killing among
isolates of S. brasiliensis, the most pathogenic among
Sporothrix species.
Spontaneous cure, as well as relapse, are common fea-
tures of sporotrichosis. Our present data show that most
antifungal agents had only a fungistatic effect against
clinical isolates. It remains unclear whether there is a
correlation between in vitro MIC/MFC data and clinical
outcome in human sporotrichosis. Experimental murine
models have shown the efficacy of posaconazole (5 mg/kg)
for treating S. brasiliensis and S. schenckii s. str. infections
[51]. Voriconazole (40 mg/kg) has been demonstrated to
only reduce fungal load in mice infected with S. schenckii
s. str., and to have no activity against S. brasiliensis [52].
No studies to date have linked the dissimilar phylogenetic
species to in vitro and in vivo data. Our in vitro results
for the highly tolerant strain CBS 133020 (=Ss265,
haplotype 7), an isolate originated from a disseminated
case of S. brasiliensis in an HIV patient [9], shown that
despite ITC and AMB MICs of 1 and 4 μg/mL, respect-
ively, and MFCs of >16 and 8 μg/mL, respectively, the
patient showed positive clinical outcome after administra-
tion of intravenous AMB (including 10 days on L-AMB)
[9], indicating a need to monitor MFCs values before and
during treatment.
Conclusions
Our study presents antifungal susceptibility profiles using
MIC and MFC data, which is particularly noteworthy in
light of recent taxonomic changes in medically relevant
Sporothrix species. We assessed a genetically diverse set of
strains with varying degrees of disease severity (fixed cuta-
neous, lymphocutaneous, or disseminated), and the anti-
fungal susceptibility assays revealed a broad spectrum for
the triazoles (ITC, PCZ, and VRC). This finding may have
implications for the choice of antifungal therapy in differ-
ent epidemiological risk groups, potentially having a sub-
stantial impact on clinical outcome. Furthermore, our data
indicate the existence of multidrug resistant strains within
Rodrigues et al. BMC Infectious Diseases 2014, 14:219 Page 7 of 9
http://www.biomedcentral.com/1471-2334/14/219
the S. schenckii complex, underlining the need for con-
tinuous susceptibility screening. Further studies should be
conducted to connect in vitro and clinical data, as well as
to investigate the molecular mechanisms underlying the
different resistance profiles among S. schenckii and its
relatives.
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